Stockscreener 앱 받기
1.51
2.58%
-0.04
전일 마감가:
$1.55
열려 있는:
$1.56
하루 거래량:
2.28M
Relative Volume:
0.84
시가총액:
$339.34M
수익:
$95,000
순이익/손실:
$-327.27M
주가수익비율:
-0.7123
EPS:
-2.12
순현금흐름:
$-239.25M
1주 성능:
+5.59%
1개월 성능:
+22.76%
6개월 성능:
+7.86%
1년 성능:
-25.25%
1일 변동 폭
$1.50
$1.565
1주일 범위
$1.39
$1.565
52주 변동 폭
$0.8621
$3.78
Allogene Therapeutics Inc Stock (ALLO) Company Profile
명칭
Allogene Therapeutics Inc
전화
(650) 457-2700
주소
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
ALLO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALLO
Allogene Therapeutics Inc
|
1.51 | 348.33M | 95,000 | -327.27M | -239.25M | -2.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-10 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2025-05-14 | 다운그레이드 | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-14 | 업그레이드 | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2024-08-08 | 재개 | Oppenheimer | Outperform |
| 2024-05-31 | 개시 | Piper Sandler | Overweight |
| 2024-01-05 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-01-05 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-08 | 개시 | Citigroup | Buy |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2023-01-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-01-06 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-12-12 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2022-08-10 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-07-15 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-06-03 | 개시 | Robert W. Baird | Neutral |
| 2022-02-28 | 재확인 | B. Riley Securities | Buy |
| 2021-10-20 | 개시 | Cowen | Outperform |
| 2021-10-08 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-10-08 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-09-23 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2021-06-21 | 재개 | Jefferies | Buy |
| 2021-05-20 | 업그레이드 | Truist | Hold → Buy |
| 2021-05-14 | 개시 | B. Riley Securities | Buy |
| 2021-01-26 | 업그레이드 | Stifel | Hold → Buy |
| 2020-12-10 | 재개 | H.C. Wainwright | Buy |
| 2020-11-24 | 개시 | BofA Securities | Buy |
| 2020-10-23 | 개시 | RBC Capital Mkts | Outperform |
| 2020-06-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-05-29 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-19 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2020-05-15 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-05-14 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-14 | 다운그레이드 | SunTrust | Buy → Hold |
| 2020-04-13 | 개시 | SunTrust | Buy |
| 2020-03-13 | 개시 | H.C. Wainwright | Buy |
| 2020-03-05 | 개시 | Stifel | Hold |
| 2020-02-24 | 개시 | Berenberg | Hold |
| 2019-12-18 | 개시 | JMP Securities | Mkt Outperform |
| 2019-11-04 | 개시 | Canaccord Genuity | Buy |
| 2019-08-09 | 개시 | BTIG Research | Buy |
| 2019-06-05 | 개시 | ROTH Capital | Neutral |
| 2019-05-31 | 개시 | Guggenheim | Neutral |
| 2019-05-23 | 개시 | Stifel | Hold |
| 2019-03-29 | 개시 | Piper Jaffray | Overweight |
모두보기
Allogene Therapeutics Inc 주식(ALLO)의 최신 뉴스
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
December 2025 Penny Stocks Worth Watching - simplywall.st
Allogene Therapeutics advances ALPHA3 trial to battle relapse fears - Traders Union
Will Allogene Therapeutics Inc. stock benefit from green energy trendsForecast Cut & Stock Market Timing Techniques - Newser
Allogene Therapeutics showcases ALPHA3 study at ASH25 - Traders Union
Allogene Therapeutics CEO unveils pipeline at Piper Sandler - Traders Union
Allogene Therapeutics Up 19%, But Some Insiders Miss Out - 富途牛牛
Allogene Therapeutics (NASDAQ:ALLO) Upgraded at Wall Street Zen - MarketBeat
U.S. CAR T-Cell Therapies Market Grows at 30.4% CAGR, Soars USD 42.61 Billion by 2035 - GlobeNewswire Inc.
Could a New Alternative to a Bespoke Treatment Change the Future of Cancer Care? - Katie Couric Media
Allogene upgraded at Citizens after Q4 update - MSN
Allogene Therapeutics redefines CAR T-cell therapy with allogeneic products - Traders Union
FDA Clears Allogene's IND for CAR T Therapy in Autoimmune Diseases - MSN
Allogene Therapeutics falls after trial delay, rating downgrade post Q1 results - MSN
Can SBC Exports Limited Deliver Through Market Peaks and TroughsResistance Zone Identification & Build Winning Portfolio - earlytimes.in
Allogene Therapeutics reports Q3 EPS (19c), consensus (23c) - MSN
Allogene Therapeutics unveils ALLO-329 to combat autoimmune diseases - Traders Union
CAR-T in NHL Treatment Market Size is estimated to grow by 2034, - openPR.com
Analyzing Allogene Therapeutics Inc. with multi timeframe chartsWeekly Stock Report & Fast Moving Trade Plans - newser.com
Detecting support and resistance levels for Allogene Therapeutics Inc.Market Movement Recap & Step-by-Step Trade Execution Guides - newser.com
[Form 4] Allogene Therapeutics, Inc. Insider Trading Activity - Stock Titan
Why Allogene Therapeutics Inc. stock remains on watchlistsPortfolio Return Summary & Risk Adjusted Buy and Sell Alerts - newser.com
Allogene Therapeutics advances ALLO-329 cell therapy to transform autoimmune care - Traders Union
ALLO (Allogene Therapeutics) Construction In Progress : $0.00 Mil (As of Sep. 2025) - GuruFocus
Patient Square Capital LP Grows Position in Allogene Therapeutics, Inc. $ALLO - MarketBeat
Will breakout in Allogene Therapeutics Inc. lead to full recovery2025 Volume Leaders & Free Verified High Yield Trade Plans - newser.com
What candlestick patterns are forming on Allogene Therapeutics Inc.Weekly Trend Recap & Reliable Price Breakout Signals - newser.com
Allogene Therapeutics at Jefferies Conference: Strategic Advances in CAR-T Therapy - Investing.com Canada
VP Beneski Files To Sell 786 Of Allogene Therapeutics Inc [ALLO] - TradingView
Applying Elliott Wave Theory to Allogene Therapeutics Inc.July 2025 Analyst Calls & Safe Capital Allocation Plans - newser.com
Risk adjusted return profile for Allogene Therapeutics Inc. analyzedQuarterly Trade Report & Low Risk Entry Point Guides - newser.com
Allogene Therapeutics CEO advocates cell therapy innovation at Jefferies conference - Traders Union
Published on: 2025-11-14 03:15:46 - newser.com
How sentiment analysis helps forecast Allogene Therapeutics Inc.2025 Top Gainers & Step-by-Step Trade Execution Guides - newser.com
Using AI based signals to follow Allogene Therapeutics Inc.2025 Market Outlook & Momentum Based Trading Ideas - newser.com
Allogene Therapeutics Inc (ALLO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.08%
0.91%
자본화:
|
볼륨(24시간):